NLS Reinstated and Recapitalised

The Company was recapitalised and reinstated to official quotation on the ASX on 14 March 2011. Completion of the recapitalisation through the capital raising of $2.5 million restructured the Company's issued capital.

DG 17 Under Development

NLSI's primary focus has been the development and commercialization of its anti-HIV protease inhibitor DG-17. DG-17 is the water-soluble pro-drug of the active anti-HIV drug DG-35.This development is occurring through the Xi'an Hex Joint Venture in China.

Queensland Coal Tenements Acquisition

Narhex Life Sciences Limited has entered into an Option Agreement to acquire key tenements in the Mulgildie Basin, the northern extension of the Surat Basin, Queensland.

Company Overview

Narhex Life Sciences Limited holds a 50% interest in Narhex Life Sciences International Pty Ltd (NLSI) with interests in Xian Hex Life Sciences Company Limited – Chinese Joint Venture, Narhex Limited and Cavidi AB.

NLSI’s primary focus has been the development and commercialization of its anti-HIV protease inhibitor DG-17. DG-17 is the water-soluble pro-drug of the active anti-HIV drug DG-35. This development is occurring through its 75% interest in the Xi’an Hex Joint Venture in China.

The Company was recently recapitalised and reinstated to official quotation on the ASX on 14 March 2011. A portion of the Company’s funds have been allocated to the examination of alternative and additional investment opportunities.

As part of the review of alternative investment opportunities, the Company has entered into an option agreement to acquire coal tenements in Central Queensland.